China’s pharmaceutical contractors are showing financial resilience in the face of Washington’s push to curb reliance on Chinese supply chains. Analysts said investors were bullish because the US government’s recent measures to curb Beijing’s rise as a global pharmaceutical supplier had met resistance from industry players reluctant to give up China’s cost advantages. Hong Kong-listed shares of WuXi AppTec, Asia’s largest provider of contract pharmaceutical research, gained 3 per cent on Monday...

Gene-editing therapies for the nervous system may need at least another round of studies before they are safe enough to enter human trials, according to one of the world’s most influential figures in the commercialisation of brain science. “The techniques are reasonably well established for animal experiments, but they really haven’t been as mature for human studies,” said Karoly Nikolich, an adjunct professor at Stanford University School of Medicine, in an exclusive interview with the South...